Abstract
A group of prominent women’s health organisations are suing the Food and Drug Administration (FDA) for preventing telemedicine prescribing of mifepristone, one of the drugs used in early abortions and miscarriages. It is the only prescription drug with such a restriction. The plaintiffs argue that the prohibition on telemedicine prescribing and mail delivery of mifepristone puts both the patient and the provider at risk of exposure to covid-19 during the current pandemic. Public health authorities have urged people to stay home as much as possible and the Centers for Disease Control and Prevention advised people to fill prescriptions by mail. Those behind the action are the American Civil Liberties Union (ACLU), the American College of Obstetricians and Gynecologists, the Council of University Chairs of …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
